About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Anti-Cancer Drug Sorafenib Increases Lifespan in Advanced Liver Cancer Patients

by Karthika on July 26, 2008 at 12:34 PM
Font : A-A+

Anti-Cancer Drug Sorafenib Increases Lifespan in Advanced Liver Cancer Patients

Researchers have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug. The findings is a significant advance in the management of liver cancer, which is the third cause of cancer death globally, often resulting in death within a year of diagnosis.

"This is the first time that we've had an effective systemic treatment for liver cancer," said Josep Llovet, MD, Director of Research in Liver Cancer at Mount Sinai School of Medicine in New York, and a Professor at the Barcelona Clinic Liver Cancer (BCLC) Group in Barcelona, Spain and lead author of the study. "Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful."

Advertisement

Sorafenib, a tablet that is taken orally, is approved in the United States for treating a form of advanced kidney cancer, and is currently being evaluated in patients with other cancers. Some 40 percent of liver cancers (and up to 80 percent in Asia and sub-Saharan Africa) are diagnosed at an advanced stage. Therapy for advanced liver cancer may include surgery (if possible), radiation therapy and/or regional chemotherapy (delivered directly into the liver). However, no systemic treatment—anti-cancer medication that enters the bloodstream, either as an oral or intravenous medicine—has proven effective to date for advanced liver cancer.

Dr. Llovet and his associates examined overall survival and the time it took for cancer to grow among patients with previously untreated liver cancer who were randomly assigned to receive either 400 mg of sorafenib twice daily (299 patients) or a placebo (303 patients).
Advertisement

Patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to the positive findings, the study was terminated early.

The incidence of adverse side effects was similar between the two groups (52 percent in the sorafenib group and 54 percent for placebo). The most common moderate to serious side effects were diarrhea (11 percent vs. 2 percent), skin reactions in the hands and feet (8 percent vs. 1 percent), fatigue (10 percent vs. 15 percent) and bleeding (6 percent vs. 9 percent).



Source: Newswise
KAR
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alcoholic Liver Disease Drug Toxicity Hepatitis A Hepatitis B Leukemia Liver Cancer Cancer and Homeopathy Chronic Myeloid Leukemia Acute Myeloid Leukemia Neonatal Jaundice 
Recommended Reading
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukem...
Alcoholic Liver Disease
Encyclopedia section of medindia gives general information about Alcoholic Liver Disease....
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. H...
Hepatitis B
Hepatitis B is inflammation of the liver due to infection with the hepatitis B virus....
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Liver Cancer
Liver or hepatic cancer is an abnormal growth of cells in the liver. The leading cause of the diseas...
Neonatal Jaundice
Yellow colouring of skin in newborns, a condition called Neonatal jaundice. , Neonatal jaundice is c...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use